


Amendments to the Claims:

This listing of claims will replace all prior version, and listing, of claims in the application.

Listing of Claims:

1. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine according to the general~~ A compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein

R¹ and R⁴ are independently from each other ~~selected~~ chosen from the group consisting of:

H; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl and C₂-C₁₀-alkynyl, the substituents of which are ~~selected~~ chosen from the group consisting of F, OH, C₁-C₈-alkoxy, (C₁-C₈-alkyl)mercapto, CN, COOR⁶, CONR⁷R⁸, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~ chosen from the group consisting of halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~ chosen from the group consisting of halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃; R⁹CO; CONR¹⁰R¹¹;

COOR¹²; CF₃; halogens; pseudohalogens; NR¹³R¹⁴; OR¹⁵; S(O)_mR¹⁶; SO₂NR¹⁷R¹⁸; and NO₂;

R² and R³ are independently from each other ~~selected~~ chosen from the group consisting of:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, the substituents of which are ~~selected~~ chosen from the group consisting of OH, phenyl, and heteroaryl; OH; C₁-C₁₀-alkoxy; phenoxy; S(O)_mR¹⁹; CF₃; CN; NO₂; (C₁-C₁₀-alkyl)amino; di(C₁-C₁₀-alkyl)amino; (C₁-C₆-alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl-SO₂-O-, the substituents of which are ~~selected~~ chosen from the group consisting of halogens, pseudohalogens, CH₃ and methoxy; (C₁-C₆-alkyl)SO₂-O-; unsubstituted and at least monosubstituted (C₁-C₆-alkyl)CO, the substituents of which are ~~selected~~ chosen from the group consisting of F, di(C₁-C₃-alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from the group consisting of C₁-C₃-alkyl, halogens and methoxy;

A is ~~selected~~ chosen from the group consisting of CH₂, CHOH and CH-(C₁-C₃-alkyl);

B is ~~selected~~ chosen from the group consisting of CH₂ and CH-(C₁-C₃-alkyl);

C independently has the same meaning as B;

D independently has the same meaning as B;

R⁵ is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~ chosen from the group consisting of: halogens; pseudohalogens; NH₂; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl,

C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-alkoxy, (C₁-C₁₀-alkyl)amino, and di(C₁-C₁₀-alkyl)amino, the substituents of which are ~~selected~~chosen from the ~~group consisting of~~ F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, NH₂, (C₁-C₈-alkyl)amino, and di(C₁-C₈-alkyl)amino; C₃-C₅-alkandiyl; phenyl; heteroaryl; aryl- or heteroaryl-substituted C₁-C₄-alkyl; CF₃; NO₂; OH; phenoxy; benzyloxy; (C₁-C₁₀-alkyl)COO; S(O)_mR²⁰; SH; phenylamino; benzylamino; (C₁-C₁₀-alkyl)-CONH-; (C₁-C₁₀-alkyl)-CON(C₁-C₄-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₄-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₄-alkyl)-; (C₁-C₁₀-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COOR²¹; CONR²²R²³; CNH(NH₂); SO₂NR²⁴R²⁵; R²⁶O₂NH-; R²⁷SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms ~~selected~~chosen from the ~~group consisting of~~ N, O, and S, which heterocycles can be substituted by one or more substituents ~~selected~~chosen from the ~~group consisting of~~ halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to the said group Ar or the said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in the said substituents of the said group Ar or the said group Hetar, can be substituted by one or more substituents ~~selected~~chosen from the ~~group consisting of~~ halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

R⁶ is ~~selected~~chosen from the ~~group consisting of~~:

H; C₁-C₁₀-alkyl, which can be substituted by one or more substituents ~~selected~~chosen from the ~~group consisting of~~ F, C₁-C₈-alkoxy, and di(C₁-C₈-alkyl)amino;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

aryl-(C₁-C₄-alkyl) and heteroaryl-(C₁-C₄-alkyl), which can be substituted by one or more substituents ~~selected~~ chosen from the group ~~consisting of~~ halogens, C₁-C₄-alkoxy, and di(C₁-C₆-alkyl)amino;

R⁷ is ~~selected~~ chosen from the group ~~consisting of~~:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents ~~selected~~ chosen from the group ~~consisting of~~ F, C₁-C₈-alkoxy, di(C₁-C₈-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from the group ~~consisting of~~ halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is ~~selected~~ chosen from the group ~~consisting of~~: C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from the group ~~consisting of~~: F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~ chosen from the group ~~consisting of~~ C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁸;

R¹² independently has the same meaning as R⁶;

R¹³ is ~~selected~~ chosen from the group ~~consisting of~~: H; C₁-C₆-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are ~~selected~~ chosen from the group ~~consisting of~~ halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is ~~selected~~chosen from the ~~group consisting of~~: H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are ~~selected~~chosen from the ~~group consisting of~~ halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is ~~selected~~chosen from the ~~group consisting of~~: C₁-C₁₀-alkyl which can be substituted by one or more substituents ~~selected~~chosen from the ~~group consisting of~~ F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, (C₁-C₈-alkyl)amino and di(C₁-C₈-alkyl)amino; CF₃; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~chosen from the ~~group consisting of~~ halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁸;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R^{27} independently has the same meaning as R^{16} .

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from the ~~group consisting of~~ N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from the ~~group consisting of~~ N, O, and S;

aryl is phenyl, naphth-1-yl or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2.

2. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine~~ The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein I_1 in the formula (I),

R^1 is ~~selected~~ chosen from the ~~group consisting of~~: H; C_1 - C_4 -alkyl; C_1 - C_4 -alkoxy; CF_3 ; halogens; pseudohalogens; $(C_1$ - C_4 -alkyl)- $S(O)_m$; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~ chosen from the ~~group consisting of~~ halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 , and wherein heteroaryl is ~~selected~~ chosen from the ~~group consisting of~~ 5- and 6-membered heterocycles containing one or more heteroatoms chosen from the ~~group consisting of~~ N, O, and S;

R^2 and R^3 are independently from each other ~~selected~~ chosen from the ~~group consisting of~~:

H; halogens; pseudohalogens; and C₁-C₃-alkyl;

R⁴ independently has the same meaning as R¹;

A is ~~selected~~ chosen from the group ~~consisting of~~ CH₂ and CHOH;

B, C and D are independently from each other ~~selected~~ chosen from the group ~~consisting of~~ CH₂ and CH-CH₃;

R⁵ is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~ chosen from the group ~~consisting of~~: halogens; CN; NH₂; unsubstituted and at least monosubstituted C₁-C₈-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkynyl, C₁-C₈-alkoxy, (C₁-C₈-alkyl)amino, and di(C₁-C₈-alkyl)amino, the substituents of which are ~~selected~~ chosen from the group ~~consisting of~~ F, C₁-C₆-alkoxy, phenoxy, (C₁-C₆-alkyl)mercapto, NH₂, (C₁-C₆-alkyl)amino, and di(C₁-C₆-alkyl)amino; C₃-C₅-alkandiyl; phenyl; heteroaryl; phenyl- or heteroaryl-substituted C₁-C₂-alkyl; CF₃; OH; phenoxy; benzyloxy; (C₁-C₆-alkyl)COO; S(O)_m(C₁-C₆-alkyl); S(O)_m-phenyl; S(O)_m-heteroaryl; SH; phenylamino; benzylamino; (C₁-C₆-alkyl)-CONH-; (C₁-C₆-alkyl)-CON(C₁-C₄-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₄-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₄-alkyl)-; (C₁-C₆-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-, -CH₂CH₂O-; COO(C₁-C₆-alkyl); -CONH₂; -CONH(C₁-C₆-alkyl); -CON(di(C₁-C₆-alkyl)); CNH(NH₂); -SO₂NH₂; -SO₂NH(C₁-C₆-alkyl); -SO₂NH(phenyl); -SO₂N(di(C₁-C₆-alkyl)); (C₁-C₆-alkyl)SO₂NH-; (C₁-C₆-alkyl)SO₂N(C₁-C₆-alkyl)-; phenyl-SO₂NH-; phenyl-SO₂N(C₁-C₆-alkyl)-; heteroaryl-SO₂NH-; heteroaryl-SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms ~~selected~~ chosen from the group ~~consisting of~~

of N, O, and S, which heterocycles can be substituted by one or more substituents ~~selected~~ chosen from the group consisting of halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to the said group Ar or the said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in the said substituents of the said group Ar or the said group Hetar, can be substituted by one or more substituents ~~selected~~ chosen from the group consisting of halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

heteroaryl is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from the group consisting of N, O, and S;

the group Hetar is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from the group consisting of N, O, and S;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0 or 2.

3. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl-amine~~ The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R¹ is H, halogen or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A, B and C are each CH₂;

D is ~~selected~~ chosen from the group consisting of CH₂ and CH-CH₃;

R⁵ is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~ chosen from the group consisting of: halogens; CN; NH₂; unsubstituted and at least monosubstituted C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₃-alkoxy, (C₁-C₄-alkyl)amino, di(C₁-C₄-alkyl)amino, the substituents of which are ~~selected~~ chosen from the group consisting of F, C₁-C₃-alkoxy, (C₁-C₃-alkyl)mercapto, and NH₂; C₃-C₅-alkandiyl; phenyl; heteroaryl; phenyl- or heteroaryl-substituted C₁-C₂-alkyl; CF₃; OH; (C₁-C₄-alkyl)COO; S(O)_m(C₁-C₄-alkyl); (C₁-C₄-alkyl)-CONH-; (C₁-C₄-alkyl)-CON(C₁-C₄-alkyl)-; (C₁-C₄-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COO(C₁-C₆-alkyl); -CONH₂; -CONH(C₁-C₄-alkyl); -CON(di(C₁-C₄-alkyl)); CNH(NH₂); -SO₂NH₂; -SO₂NH(C₁-C₄-alkyl); -SO₂NH(phenyl); -SO₂N(di(C₁-C₄-alkyl)); (C₁-C₄-alkyl)SO₂NH-; (C₁-C₄-alkyl)SO₂N(C₁-C₄-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms ~~selected~~ chosen from the group consisting of N, O, and S, which heterocycles can be substituted by one or more substituents ~~selected~~ chosen from the group consisting of halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to the said phenyl or the said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in the said substituents of the said phenyl or the said group Hetar, can be substituted by one or more substituents ~~selected~~ chosen from the group consisting of halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

heteroaryl is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms ~~selected~~ chosen from the group consisting of N, O, and S;

the group Hetar is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms ~~selected~~ chosen from the group consisting of N, O, and S; and

m is 0 or 2.

4. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl-amine~~ The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R¹ is H, halogen or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A, B and C are each CH₂;

D is ~~selected~~ chosen from the group consisting of CH₂ and CH-CH₃;

R⁵ is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~ chosen from the group consisting of: F; Cl; Br; C₁-C₃-alkyl; C₁-C₃-alkoxymethyl; 2-amino-3,3,3-trifluoro-propyl-; CF₃; C₃-C₅-alkandyl; phenyl; heteroaryl; benzyl; heteroaryl-methyl; OH; C₁-C₃-alkoxy; phenoxy; trifluoromethoxy; 2,2,2-trifluoroethoxy; (C₁-C₄-alkyl)COO; (C₁-C₃-alkyl)mercapto; phenylmercapto; (C₁-C₃-alkyl)sulfonyl; phenylsulfonyl; NH₂; (C₁-C₄-alkyl)amino; di(C₁-C₄-alkyl)amino; (C₁-C₃-alkyl)-CONH-; (C₁-C₃-alkyl)-SO₂NH-; (C₁-C₃-alkyl)-CO; phenyl-CO; -OCH₂O-;

-OCF₂O-; -CH₂CH₂O-; COO(C₁-C₄-alkyl); -CONH₂; -CONH(C₁-C₄-alkyl);
-CON(di(C₁-C₄-alkyl)); CN; -SO₂NH₂; -SO₂NH(C₁-C₄-alkyl); -SO₂N(di(C₁-C₄-alkyl));
pyrrolidinyl; piperidinyl; morpholinyl; and thiomorpholinyl; and wherein all heteroaryl,
phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally
present in the said substituents of the said phenyl or the said group Heter, can be
substituted by one or more substituents ~~selected~~ chosen from the group consisting of
halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

heteroaryl is ~~selected~~ chosen from the group consisting of: furyl, pyrrolyl, thienyl,
thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl,
pyridyl, pyrimidinyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl,
isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and
indazolyl; and

the group Heter is ~~selected~~ chosen from the group consisting of: furyl, pyrrolyl,
thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl,
pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzthiazolyl, benzoxazolyl, quinolinyl,
isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and
indazolyl.

5. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-~~
~~benzocycloheptenyl amine~~ The compound of formula (I) in any of its stereoisomeric
forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof
according to claim 1, wherein, in the formula (I),

R¹ is H, halogen or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A, B and C are each CH₂;

D is ~~selected~~ chosen from the group consisting of CH₂ and CH-CH₃; and

R⁵ is ~~selected~~ chosen from the group consisting of: 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-(C₁-C₃-alkoxy)-phenyl, 4-trifluoromethoxyphenyl, 2-bromo-4-fluorophenyl, 2-chloro-4-fluorophenyl, 3,4-dimethylphenyl, 2,4-dimethylphenyl, 4-chloro-2-methylphenyl, 2-hydroxy-4-methylphenyl, 2-hydroxy-4-ethoxyphenyl, 2-methoxy-4-methylphenyl, 4-phenoxyphenyl, 3-fluoro-4-methylphenyl, benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-yl, 1-(4-fluoro-phenyl)-3,5-dimethyl-1H-pyrazole-4-yl, 1H-benzotriazole-5-yl, 1H-indole-4-yl, 1H-indole-6-yl, 1-isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-yl, 1-methyl-3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-yl, 1-phenyl-5-trifluoromethyl-1H-pyrazole-4-yl, 2-(2-hydroxy-pyridin-4-yl)-1H-benzoimidazole-5-yl, 2-(4-cyano-phenyl)-1H-benzoimidazole-5-yl, 2,4-dimethyl-oxazole-5-yl, 2,4-dimethyl-pyrimidine-5-yl, 2,4-dimethyl-thiazole-5-yl, 2,5-dimethyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrolyl, 2,5-dimethyl-2H-pyrazole-3-yl, 2,6-dichloro-pyrid-3-yl, 2,6-dimethoxy-pyrid-3-yl, 2,6-dimethyl-pyrid-3-yl, 2-amino-4,6-dimethyl-pyrid-3-yl, 2-amino-6-chloro-pyrid-3-yl, 2-amino-pyrid-3-yl, 2-chloro-6-methyl-pyrid-3-yl, 2-chloro-pyrid-4-yl, 2-cyclopropyl-4-methyl-thiazole-5-yl, 2-dimethylamino-4-methyl-thiazole-5-yl, 2-dimethylamino-pyrid-4-yl, 2-ethyl-5-methyl-2H-pyrazole-3-yl, 2-hydroxy-6-methyl-pyrid-3-yl, 2-methyl-1H-benzoimidazole-5-yl, 2-methyl-3H-benzoimidazole-5-yl, 2-methyl-pyrid-3-yl, 2-methyl-6-trifluoromethyl-pyrid-3-yl,

2-methyl-thiazole-5-yl, 2-morpholin-4-yl-pyridin-4-yl, 2-morpholin-4-yl-pyrimidine-5-yl, 2-pyrrolidin-1-yl-pyridin-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, 3-amino-5,6-dimethyl-pyrazine-2-yl, 3-amino-5-methyl-pyrazine-2-yl, 3-amino-pyrazine-2-yl, 3-dimethylamino-4-methyl-phenyl, 3-dimethylamino-phenyl, 3H-benzoimidazole-5-yl, 1H-benzoimidazole-5-yl, 3-methanesulfonylamino-2-methyl-phenyl, 3-methanesulfonylamino-phenyl, 3-methyl-isoxazole-4-yl, 3-morpholin-4-yl-phenyl, 3-piperidin-1-yl-phenyl, 3-pyrrolidin-1-yl-phenyl, 4-(2,2,2-trifluoro-ethoxy)-phenyl, 4,6-dimethyl-pyrid-3-yl, 4-amino-2-ethylsulfanyl-pyrimidine-5-yl, 4-amino-2-methyl-pyrimidine-5-yl, 4-chloro-3-methanesulfonylamino-phenyl, 4-chloro-3-sulfamoyl-phenyl, 4-methyl-3-methylamino-phenyl, 4-methyl-thiazole-5-yl, pyridine-2-yl, 5,6,7,8-tetrahydro-quinoline-3-yl, 5-amino-1-phenyl-1H-pyrazole-4-yl, 5-methanesulfonyl-2-methyl-phenyl, 5-methyl-1-phenyl-1H-pyrazole-4-yl, 5-methyl-isoxazole-3-yl, 5-methyl-pyrid-3-yl, 5-methyl-pyrazine-2-yl, 6-chloro-pyrid-3-yl, 6-cyano-pyrid-3-yl, 6-dimethylamino-pyrid-3-yl, 6-ethynyl-pyrid-3-yl, 6-methoxymethyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-methyl-2-methylamino-pyrid-3-yl, 6-methylamino-pyrazine-2-yl, 6-methyl-pyrid-3-yl, 6-morpholin-4-yl-pyrid-3-yl, 6-pyrrolidin-1-yl-pyrid-3-yl, imidazo[1,2-a]pyridine-2-yl, 6-trifluoromethyl-pyrid-3-yl, and pyrimidine-4-yl.

6. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine~~ The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, selected chosen from the group consisting of:

2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrole-3-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 5-methyl-1-phenyl-1H-pyrazole-4-

carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 1H-indole-6-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 5-methylpyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-methyl-3H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-methyl-1H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-amino-6-chloro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-4-(2,2,2-trifluoro-ethoxy)-benzamide, 6-pyrrolidin-1-yl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 6-methyl-2-methylamino-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 3-amino-5,6-dimethyl-pyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 4-fluoro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide, 3-pyrrolidin-1-yl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide, 2,4-dimethyl-thiazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-amino-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 2,6-dimethyl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 3-amino-5-methyl-pyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, and 3-amino-pyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide.

7. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 1 in any of its

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

8. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 2 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

9. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 3 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

10. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 4 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

11. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 5 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

12. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 6 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

13. (withdrawn): A method according to any one of claims 7 to 12 wherein said mammal is a human.

14. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 1 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

15. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable

angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 2 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

16. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 3 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

17. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 4 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

18. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary

hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 5 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

19. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 6 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

20. (withdrawn): A method according to any one of claims 14 to 19 wherein said mammal is a human.

21. (withdrawn): A method according to only one of claims 14 to 19 wherein the disease is selected from the group consisting of endothelial dysfunction, hypertension, coronary heart disease, stable angina pectoris, diabetes complications and atherosclerosis.

22. (original): A pharmaceutical preparation comprising an effective dose of at least one compound of the formula (I) as defined in claim 1 in any of its stereoisomeric forms or a mixture thereof in any ratio and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

23. (currently amended): AThe pharmaceutical preparation according to claim 22, ~~which~~ wherein said pharmaceutical preparation is in the form of a pill, tablet, lacquered tablet, sugar-coated tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic systems, nasal spray, aerosol mixture, microcapsule, implant or rod.

24. (new): The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R⁵ is chosen from 4-fluorophenyl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 6-methoxymethyl-pyrid-3-yl, 2-methyl-1H-benzimidazole-5-yl, and 2-methyl-3H-benzimidazole-5-yl.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

25. (new): The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

each of the groups R^1 , R^2 , R^3 , and R^4 is H and each of the groups A, B, C, and D is CH_2 .

26. (new): The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, chosen from 4-fluoro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide, 2-methyl-3H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, and 2-methyl-1H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide.

27. (new): (S)-6-methoxymethyl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide or a pharmaceutically acceptable salt thereof.

28. (new): (S)-2-methyl-3H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide or a pharmaceutically acceptable salt thereof.